Michael Behnes

List of Publications by Year
in descending order

147 papers	1,810 citations	318942 23 h-index	406436 35 g-index
150 all docs	150 docs citations	150 times ranked	2765 citing authors

#	Article	IF	Citations
1	Acute oesophageal safety of high-power short duration with 50 W for atrial fibrillation ablation. Europace, 2022, 24, 928-937.	0.7	19
2	Prognostic value of beta-blocker doses in patients with ventricular tachyarrhythmias. Heart and Vessels, 2022, , 1.	0.5	1
3	Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study. American Journal of Cardiovascular Drugs, 2022, 22, 535-544.	1.0	9
4	Cardiac disease and prognosis associated with ventricular tachyarrhythmias in young adults and adults. BMC Cardiovascular Disorders, 2022, 22, 136.	0.7	0
5	Safety aspects of very high power very short duration atrial fibrillation ablation using a modified radiofrequency RFâ€generator: Singleâ€center experience. Journal of Cardiovascular Electrophysiology, 2022, 33, 920-927.	0.8	18
6	Angiotensin Converting Enzyme Inhibitors versus Receptor Blockers in Patients with Ventricular Tachyarrhythmias. Journal of Clinical Medicine, 2022, 11, 1460.	1.0	1
7	Effect of Mineralocorticoid Receptor Antagonists on the Prognosis of Patients with Ventricular Tachyarrhythmias. Pharmacology, 2022, 107, 35-45.	0.9	1
8	Efficacy and safety of highâ€power short duration atrial fibrillation ablation in elderly patients. Journal of Cardiovascular Electrophysiology, 2022, 33, 1425-1434.	0.8	6
9	Prognostic Value of Cardiac Troponin I in Patients with Ventricular Tachyarrhythmias. Journal of Clinical Medicine, 2022, 11, 2987.	1.0	2
10	Kidney Failure among Patients with Takotsubo Syndrome or Myocardial Infarction: A Retrospective Analysis. Journal of Cardiovascular Development and Disease, 2022, 9, 186.	0.8	0
11	Anosmia Testing as Early Detection of SARS-CoV-2 Positivity; A Prospective Study under Screening Conditions. Life, 2022, 12, 968.	1.1	2
12	Digitalis therapy in patients with ventricular tachyarrhythmias. Scandinavian Cardiovascular Journal, 2022, 56, 198-207.	0.4	1
13	Long-Term Outcomes after Catheter Ablation of Ventricular Tachycardia in Dilated vs. Ischemic Cardiomyopathy. Journal of Clinical Medicine, 2022, 11, 4000.	1.0	1
14	Prognostic impact of coronary chronic total occlusion on recurrences of ventricular tachyarrhythmias and ICD therapies. Clinical Research in Cardiology, 2021, 110, 281-291.	1.5	5
15	No impact of mineralocorticoid receptor antagonists on longâ€term recurrences of ventricular tachyarrhythmias. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 213-224.	0.5	1
16	Comparable risk of recurrent ventricular tachyarrhythmias in implantable cardioverterâ€defibrillator recipients treated with single betaâ€blocker or combined amiodarone. Basic and Clinical Pharmacology and Toxicology, 2021, 128, 493-502.	1.2	3
17	Chronic kidney disease impairs prognosis in electrical storm. Journal of Interventional Cardiac Electrophysiology, 2021, , 1.	0.6	0
18	Prognostic Impact of Percutaneous Coronary Intervention of Chronic Total Occlusion in Acute and Periprocedural Myocardial Infarction. Journal of Clinical Medicine, 2021, 10, 258.	1.0	9

#	Article	IF	Citations
19	Copeptin reliably reflects longitudinal right ventricular function. Annals of Clinical Biochemistry, 2021, 58, 000456322198936.	0.8	0
20	Incomplete neo-endothelialization of left atrial appendage closure devices is frequent after 6Âmonths: a pilot imaging study. International Journal of Cardiovascular Imaging, 2021, 37, 2291-2298.	0.7	9
21	Electrical storm reveals worse prognosis compared to myocardial infarction complicated by ventricular tachyarrhythmias in ICD recipients. Heart and Vessels, 2021, 36, 1701-1711.	0.5	3
22	Narrative review of metabolomics in cardiovascular disease. Journal of Thoracic Disease, 2021, 13, 2532-2550.	0.6	20
23	Pharmacological Treatment Following Myocardial Infarction: How Large Is the Gap Between Guideline Recommendations and Routine Clinical Care?. Journal of the American Heart Association, 2021, 10, e021799.	1.6	5
24	Global Chronic Total Occlusion CrossingÂAlgorithm. Journal of the American College of Cardiology, 2021, 78, 840-853.	1.2	111
25	Effect of Anemia on the Prognosis of Patients with Ventricular Tachyarrhythmias. American Journal of Cardiology, 2021, 154, 54-62.	0.7	0
26	Feasibility and outcome of the Rotapro system in treating severely calcified coronary lesions: The Rotapro study. Cardiology Journal, 2021, , .	0.5	1
27	Galectin-3 reflects the echocardiographic quantification of right ventricular failure. Scandinavian Cardiovascular Journal, 2021, 55, 362-370.	0.4	1
28	Clinical outcome of out-of-hospital vs. in-hospital cardiac arrest survivors presenting with ventricular tachyarrhythmias. Heart and Vessels, 2021, , 1.	0.5	1
29	Coronary Artery Disease in Patients Presenting With Acute Ischemic Stroke or Transient Ischemic Attack and Elevated Troponin Levels. Frontiers in Neurology, 2021, 12, 781553.	1.1	3
30	Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes. Revista Espanola De Cardiologia (English Ed), 2021, , .	0.4	0
31	In-Hospital Outcomes After Recanalization of Ostial Chronic Total Occlusions. Cardiovascular Revascularization Medicine, 2020, 21, 661-665.	0.3	4
32	Improved Outcome of Cardiogenic Shock Triggered by Takotsubo Syndrome Compared With Myocardial Infarction. Canadian Journal of Cardiology, 2020, 36, 860-867.	0.8	7
33	Patient Selection for Protected Percutaneous Coronary Intervention. Cardiology Clinics, 2020, 38, 507-516.	0.9	3
34	Association Between Mortality and Left Ventricular Ejection Fraction in Patients With Takotsubo Syndrome Versus Acute Coronary Syndrome. In Vivo, 2020, 34, 3639-3648.	0.6	2
35	The Use of Beta Blockers in Takotsubo Syndrome as Compared to Acute Coronary Syndrome. Frontiers in Pharmacology, 2020, 11, 681.	1.6	6
36	â€˜Offâ€pumpâ€™ left ventricular reconstruction â€“ A causal and less invasive surgical option for patients with advanced systolic heart failure?. European Journal of Heart Failure, 2020, 22, 581-583.	2.9	0

#	Article	IF	Citations
37	Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Future Cardiology, 2020, 16, 227-236.	0.5	16
38	Non-ischemic compared to ischemic cardiomyopathy is associated with increasing recurrent ventricular tachyarrhythmias and ICD-related therapies. Journal of Electrocardiology, 2020, 59, 174-180.	0.4	6
39	Prognostic impact of potassium levels in patients with ventricular tachyarrhythmias. Clinical Research in Cardiology, 2020, 109, 1292-1306.	1.5	3
40	Impact of Left Ventricular Ejection Fraction on Recurrent Ventricular Tachyarrhythmias in Recipients of Implantable Cardioverter Defibrillators. Cardiology, 2020, 145, 359-369.	0.6	4
41	Coronary chronic total occlusions and mortality in patients with ventricular tachyarrhythmias. EuroIntervention, 2020, 15, 1278-1285.	1.4	13
42	The role of intravascular ultrasound in the treatment of chronic total occlusion with percutaneous coronary intervention. Cardiology Journal, 2020, 27, 4-5.	0.5	3
43	The atherogenic index of plasma and its impact on recanalization of chronic total occlusion. Cardiology Journal, 2020, 27, 756-761.	0.5	9
44	Hypokalemia but not Hyperkalemia is Associated with Recurrences of Ventricular Tachyarrhythmias in ICD Recipients. Clinical Laboratory, 2020, 66, .	0.2	8
45	Risk factor paradox: No prognostic impact of arterial hypertension and smoking in patients with ventricular tachyarrhythmias. Cardiology Journal, 2020, 27, 715-725.	0.5	2
46	Discriminating factors excluding patients from a catheter-based left atrial appendage closure and anÂoutcome analysis ofÂnon-intervened and intervened patients. Archives of Medical Science, 2020, , .	0.4	0
47	Relation of left atrial appendage closure devices to topographic neighboring structures using standardized imaging by cardiac computed tomography angiography. Clinical Cardiology, 2019, 42, 264-269.	0.7	12
48	Digitalis Therapy and Risk of Recurrent Ventricular Tachyarrhythmias and ICD Therapies in Atrial Fibrillation and Heart Failure. Cardiology, 2019, 142, 129-140.	0.6	4
49	Takotsubo syndrome and cardiac implantable electronic device therapy. Scientific Reports, 2019, 9, 16559.	1.6	12
50	Atrial Fibrillation Is Associated with Increased Mortality in Patients Presenting with Ventricular Tachyarrhythmias. Scientific Reports, 2019, 9, 14291.	1.6	6
51	Prognostic Impact of Atrial Fibrillation in Electrical Storm. Cardiology, 2019, 144, 9-17.	0.6	0
52	Impact of Different Pharmacotherapies on Long-Term Outcomes in Patients with Electrical Storm. Pharmacology, 2019, 103, 179-188.	0.9	3
53	Extravascular compared to Intravascular Femoral Closure is Associated with Less Bleeding and Similar MACE after Percutaneous Coronary Intervention. International Journal of Medical Sciences, 2019, 16, 43-50.	1.1	2
54	Increasing age is associated with recurrent ventricular tachyarrhythmias and appropriate ICD therapies secondary to documented index ventricular tachyarrhythmias. European Geriatric Medicine, 2019, 10, 567-576.	1.2	3

#	Article	IF	Citations
55	Statin therapy is associated with improved survival in patients with ventricular tachyarrhythmias. Lipids in Health and Disease, 2019, 18, 119.	1.2	6
56	The association of high-sensitivity cardiac troponin I and T with echocardiographic stages of heart failure with preserved ejection fraction. Annals of Clinical Biochemistry, 2019, 56, 431-441.	0.8	0
57	Electrical storm is associated with impaired prognosis compared to ventricular tachyarrhythmias. International Journal of Cardiology, 2019, 292, 119-125.	0.8	5
58	Impact of chronic kidney disease on recurrent ventricular tachyarrhythmias in ICD recipients. Heart and Vessels, 2019, 34, 1811-1822.	0.5	6
59	Prognostic impact of recurrences in patients with electrical storm. Scandinavian Cardiovascular Journal, 2019, 53, 71-76.	0.4	1
60	Short- and Long-Term Incidence of Thromboembolic Events in Takotsubo Syndrome as Compared With Acute Coronary Syndrome. Angiology, 2019, 70, 838-843.	0.8	12
61	Impact of ST-segment elevation on the outcome of Takotsubo syndrome . Therapeutics and Clinical Risk Management, 2019, Volume 15, 251-258.	0.9	3
62	Impact of Tâ€inversion on the outcome of Takotsubo syndrome as compared to acute coronary syndrome. European Journal of Clinical Investigation, 2019, 49, e13078.	1.7	3
63	Prognostic impact of recurrences of ventricular tachyarrhythmias and appropriate ICD therapies in a high-risk ICD population. Clinical Research in Cardiology, 2019, 108, 878-891.	1.5	9
64	Prognostic impact of left ventricular ejection fraction in patients with electrical storm. Journal of Interventional Cardiac Electrophysiology, 2019, 55, 307-315.	0.6	3
65	Prognostic Impact of Angiotensin-Converting Enzyme Inhibitors and Receptor Blockers on Recurrent Ventricular Tachyarrhythmias and Implantable Cardioverterâ€“Defibrillator Therapies. Journal of Cardiovascular Pharmacology, 2019, 73, 272-281.	0.8	2
66	Comparable survival in ischemic and nonischemic cardiomyopathy secondary to ventricular tachyarrhythmias and aborted cardiac arrest. Coronary Artery Disease, 2019, 30, 303-311.	0.3	3
67	Differences of bleedings after percutaneous coronary intervention using femoral closure and radial compression devices. Medicine (United States), 2019, 98, e15501.	0.4	3
68	Prognostic impact of chronic kidney disease and renal replacement therapy in ventricular tachyarrhythmias and aborted cardiac arrest. Clinical Research in Cardiology, 2019, 108, 669-682.	1.5	13
69	Prognostic impact of beta-blocker compared to combined amiodarone therapy secondary to ventricular tachyarrhythmias. International Journal of Cardiology, 2019, 277, 118-124.	0.8	7
70	Assessment of peri-device leaks after interventional left atrial appendage closure using standardized imaging by cardiac computed tomography angiography. International Journal of Cardiovascular Imaging, 2019, 35, 725-731.	0.7	17
71	Optimal medical therapy vs. coronary revascularization for patients presenting with chronic total occlusion: A metaâ€analysis of randomized controlled trials and propensity score adjusted studies. Catheterization and Cardiovascular Interventions, 2019, 93, E320-E325.	0.7	15
72	Male sex increases mortality in ventricular tachyarrhythmias. Internal Medicine Journal, 2019, 49, 711-721.	0.5	3

#	Article	IF	Citations
73	Optimal duration for dual antiplatelet therapy with COMBO dual therapy stent. Journal of Geriatric Cardiology, 2019, 16, 840-843.	0.2	0
74	Impact of left atrial appendage morphology on thrombus formation after successful left atrial appendage occlusion: Assessment with cardiac-computed-tomography. Scientific Reports, 2018, 8, 1670.	1.6	19
75	High sensitivity troponin T and I reflect left atrial function being assessed by cardiac magnetic resonance imaging. Annals of Clinical Biochemistry, 2018, 55, 264-275.	0.8	2
76	Lack of silent cerebral ischemic events: a case series of patients after left atrial appendage closure. Clinical Research in Cardiology, 2018, 107, 91-93.	1.5	2
77	Revisiting the prognostic value of monocyte chemotactic protein 1 and interleukin-6 in the sepsis-3 era. Journal of Critical Care, 2018, 43, 21-28.	1.0	29
78	Peri-interventional embolization of left atrial appendage occlusion devices: two manoeuvers of successful retrieval. European Heart Journal - Case Reports, 2018, 2, yty001.	0.3	4
79	COPD increases cardiac mortality in patients presenting with ventricular tachyarrhythmias and aborted cardiac arrest. Respiratory Medicine, 2018, 145, 153-160.	1.3	5
80	Shortâ€term and longâ€term incidence of stroke in Takotsubo syndrome. ESC Heart Failure, 2018, 5, 1191-1194.	1.4	8
81	Prognostic Impact of Acute Myocardial Infarction in Patients Presenting With Ventricular Tachyarrhythmias and Aborted Cardiac Arrest. Journal of the American Heart Association, 2018, 7, e010004.	1.6	24
82	Type 2 diabetes is independently associated with all-causeÂmortality secondary to ventricular tachyarrhythmias. Cardiovascular Diabetology, 2018, 17, 125.	2.7	27
83	A Randomized Trial to Assess Regional Left Ventricular Function After Stent Implantation in Chronic Total Occlusion. JACC: Cardiovascular Interventions, 2018, 11, 1982-1991.	1.1	111
84	Galectin-3 Reflects the Echocardiographic Grades of Left Ventricular Diastolic Dysfunction. Annals of Laboratory Medicine, 2018, 38, 306-315.	1.2	22
85	Beta-Blockers and ACE Inhibitors Are Associated with Improved Survival Secondary to Ventricular Tachyarrhythmia. Cardiovascular Drugs and Therapy, 2018, 32, 353-363.	1.3	16
86	Interventional Left Atrial Appendage Closure Affects the Metabolism of Acylcarnitines. International Journal of Molecular Sciences, 2018, 19, 500.	1.8	7
87	Clinical outcomes associated with catecholamine use in patients diagnosed with Takotsubo cardiomyopathy. BMC Cardiovascular Disorders, 2018, 18, 54.	0.7	35
88	Real-world experience comparing two common left atrial appendage closure devices. BMC Cardiovascular Disorders, 2018, 18, 171.	0.7	17
89	Successful Percutaneous Coronary Intervention Improves Cardiopulmonary Exercise Capacity in Patients With Chronic Total Occlusions. Journal of the American College of Cardiology, 2017, 69, 1095-1096.	1.2	27
90	Procedural success and intraâ€hospital outcome related to left atrial appendage morphology in patients that receive an interventional left atrial appendage closure. Clinical Cardiology, 2017, 40, 566-574.	0.7	10

#	Article	IF	Citations
91	Arterial access-site complications after use of a vascular closure device related to puncture height. BMC Cardiovascular Disorders, 2017, 17, 64.	0.7	2
92	Impact and management of left ventricular function on the prognosis of Takotsubo syndrome. European Journal of Clinical Investigation, 2017, 47, 477-485.	1.7	14
93	Clinical outcomes of femoral closure compared to radial compression devices following percutaneous coronary intervention: the FERARI study. Heart and Vessels, 2017, 32, 520-530.	0.5	4
94	Percutaneous Coronary Intervention of Chronic Total Occlusions in Patients With Low Left Ventricular Ejection Fraction. JACC: Cardiovascular Interventions, 2017, 10, 2158-2170.	1.1	79
95	Percutaneous Closure of Left Atrial Appendage affects Mid-Term Release of MR-proANP. Scientific Reports, 2017, 7, 9028.	1.6	11
96	Retrograde Chronic Total Occlusion Percutaneous Coronary Intervention Through Ipsilateral Collateral Channels. JACC: Cardiovascular Interventions, 2017, 10, 1489-1497.	1.1	26
97	Incidence and Prognostic Relevance of Cardiopulmonary Failure in Takotsubo Cardiomyopathy. Scientific Reports, 2017, 7, 14673.	1.6	9
98	Impact of concomitant atrial fibrillation on the prognosis of Takotsubo cardiomyopathy. Europace, 2017, 19, 1288-1292.	0.7	54
99	Comparison of the ipsiâ€lateral versus contraâ€lateral retrograde approach of percutaneous coronary interventions in chronic total occlusions. Catheterization and Cardiovascular Interventions, 2017, 89, 649-655.	0.7	19
100	Diagnostic value of Pentraxin-3 in patients with sepsis and septic shock in accordance with latest sepsis-3 definitions. BMC Infectious Diseases, 2017, 17, 554.	1.3	50
101	High Sensitivity Troponins Discriminate Different Morphologies of Coronary Artery Plaques Being Assessed by Coronary Computed Tomography Angiography. Disease Markers, 2017, 2017, 1-9.	0.6	2
102	Editorial: Circulating Biomarkers in Cardiovascular Diseases â€“ A Field of Theoretical Research or Realistic Clinical Application?. Current Pharmaceutical Biotechnology, 2017, 18, 442-444.	0.9	1
103	Comparative analysis of high-sensitivity cardiac troponin I and T for their association with coronary computed tomography-assessed calcium scoring represented by the Agatston score. European Journal of Medical Research, 2017, 22, 47.	0.9	7
104	High sensitivity troponin T and I reflect mitral annular plane systolic excursion being assessed by cardiac magnetic resonance imaging. European Journal of Medical Research, 2017, 22, 38.	0.9	4
105	The Use of Biomarkers in Sepsis: A Systematic Review. Current Pharmaceutical Biotechnology, 2017, 18, 499-507.	0.9	47
106	High Sensitivity Troponin I and T Reflect the Presence of Obstructive and Multi-Vessel Coronary Artery Disease Being Assessed by Coronary Computed Tomography Angiography. Current Pharmaceutical Biotechnology, 2017, 18, 508-515.	0.9	7
107	Advantages and Limitations of Current Biomarker Research: From Experimental Research to Clinical Application. Current Pharmaceutical Biotechnology, 2017, 18, 445-455.	0.9	24
108	Contribution and Value of Biomarkers in Acute Aortic Syndromes. Current Pharmaceutical Biotechnology, 2017, 18, 495-498.	0.9	2

#	Article	IF	Citations
109	An Expanding Role of Biomarkers in Pulmonary Arterial Hypertension. Current Pharmaceutical Biotechnology, 2017, 18, 491-494.	0.9	10
110	Clinically Relevant Biomarkers in Acute Heart Failure: An Update. Current Pharmaceutical Biotechnology, 2017, 18, 482-490.	0.9	2
111	Biomarkers in Cardiomyopathies and Prediction of Sudden Cardiac Death. Current Pharmaceutical Biotechnology, 2017, 18, 472-481.	0.9	15
112	Biomarkers in Stable Coronary Artery Disease. Current Pharmaceutical Biotechnology, 2017, 18, 456-471.	0.9	33
113	â€œSpiral stentingâ€â€”creating a subintimal neo-luminal helix around a massively calcified ostial chronic total occlusion of the right coronary artery in a patient with recurrent ventricular tachycardia. Journal of Thoracic Disease, 2016, 8, E1564-E1569.	0.6	2
114	New definitions for septic shockâ€”a roadmap for a better clinical outcome?. Journal of Thoracic Disease, 2016, 8, E600-E603.	0.6	1
115	Solid Right Ventricular Compression by Intraventricular Septum-Hematoma Induced after Percutaneous Coronary Intervention. Case Reports in Cardiology, 2016, 2016, 1-4.	0.1	3
116	Galectin-3 Reflects Mitral Annular Plane Systolic Excursion Being Assessed by Cardiovascular Magnetic Resonance Imaging. Disease Markers, 2016, 2016, 1-9.	0.6	4
117	Hyperthermia Influences the Effects of Sodium Channel Blocking Drugs in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. PLoS ONE, 2016, 11, e0166143.	1.1	28
118	Left atrial appendage morphology, echocardiographic characterization, procedural data and in-hospital outcome of patients receiving left atrial appendage occlusion device implantation: a prospective observational study. BMC Cardiovascular Disorders, 2016, 16, 25.	0.7	12
119	Veno-venous double lasso pull-and-push technique for transseptal retrieval of an embolized Watchman occluder. Cardiovascular Revascularization Medicine, 2016, 17, 206-208.	0.3	7
120	Characteristics and long-term outcome of right ventricular involvement in Takotsubo cardiomyopathy. International Journal of Cardiology, 2016, 220, 371-375.	0.8	40
121	Liver and cholestatic parameters as prognostic biomarkers of inâ€hospital <scp>MACE</scp> in patients with <scp>STEMI</scp>. European Journal of Clinical Investigation, 2016, 46, 721-729.	1.7	10
122	- LAA Occluder View for post-implantation Evaluation (LOVE) - standardized imaging proposal evaluating implanted left atrial appendage occlusion devices by cardiac computed tomography. BMC Medical Imaging, 2016, 16, 25.	1.4	29
123	Biomarker evaluation as a potential cause of gender differences in obesity paradox among patients with STEMI. Cardiovascular Revascularization Medicine, 2016, 17, 88-94.	0.3	6
124	Endothelial cell-specific moleculeâ€“1/endocan: Diagnostic and prognostic value in patients suffering from severe sepsis and septic shock. Journal of Critical Care, 2016, 31, 68-75.	1.0	45
125	Triple head-to-head comparison of fibrotic biomarkers galectin-3, osteopontin and gremlin-1 for long-term prognosis in suspected and proven acute heart failure patients. International Journal of Cardiology, 2016, 203, 398-406.	0.8	13
126	Comparison of Serum Uric Acid, Bilirubin, and C-Reactive Protein as Prognostic Biomarkers of In-Hospital MACE Between Women and Men With ST-Segment Elevation Myocardial Infarction. Angiology, 2016, 67, 272-280.	0.8	31

#	Article	IF	Citations
127	Clinical and echocardiographic analysis of patients suffering from recurrent takotsubo cardiomyopathy. Journal of Geriatric Cardiology, 2016, 13, 888-893.	0.2	21
128	Expression of Inflammation-related Intercellular Adhesion Molecules in Cardiomyocytes In Vitro and Modulation by Pro-inflammatory Agents. In Vivo, 2016, 30, 213-7.	0.6	1
129	Response to Letter Regarding Article, â€œEffect of Tumor Necrosis Factor Inhibitor Treatment on Proximal Right Coronary Chronic Total Occlusion in a Patient With Rheumatoid Arthritisâ€. Circulation, 2015, 132, e163.	1.6	0
130	Design and Rationale of the Femoral Closure versus Radial Compression Devices Related to Percutaneous Coronary Interventions (FERARI) Study. Clinical Medicine Insights: Cardiology, 2015, 9, CMC.S31932.	0.6	5
131	New Oral Anticoagulants in Coronary Artery Disease. Cardiovascular & Hematological Disorders Drug Targets, 2015, 15, 101-105.	0.2	5
132	Coronary artery perforation in a patient with STEMI and a myocardial bridge: an increased risk for coronary artery perforation?. Cardiovascular Revascularization Medicine, 2015, 16, 246-248.	0.3	7
133	Effect of Tumor Necrosis Factor Inhibitor Treatment on Proximal Right Coronary Chronic Total Occlusion in a Patient With Rheumatoid Arthritis. Circulation, 2015, 131, e26-8.	1.6	5
134	Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure - diagnostic and prognostic insights compared to NT-proBNP and troponin I. BMC Cardiovascular Disorders, 2015, 15, 50.	0.7	44
135	Connective tissue growth factor (CTGF/CCN2): diagnostic and prognostic value in acute heart failure. Clinical Research in Cardiology, 2014, 103, 107-116.	1.5	26
136	Submillisievert ECG-gated whole thoracic CT-angiography for evaluation of a complex congenital heart defect in a young woman. International Journal of Cardiology, 2014, 176, e54-e55.	0.8	2
137	Treatment Optimization of Aortocoronary Dissection as a Complication After Heart Catheterization Using Coronary Computerized Tomographic Angiography. Canadian Journal of Cardiology, 2014, 30, 696.e13-696.e15.	0.8	1
138	Intercellular adhesion molecule 1 (ICAM-1) - A new substrate for the development of ventricular fibrillation?. International Journal of Cardiology, 2013, 168, 4917-4919.	0.8	0
139	Biventricular Takotsubo Cardiomyopathy in a Heart Transplant Recipient. Circulation, 2013, 128, e62-3.	1.6	18
140	Diagnostic and prognostic value of osteopontin in patients with acute congestive heart failure. European Journal of Heart Failure, 2013, 15, 1390-1400.	2.9	28
141	Alterations of Adiponectin in the Course of Inflammation and Severe Sepsis. Shock, 2012, 38, 243-248.	1.0	11
142	Alterations of leptin in the course of inflammation and severe sepsis. BMC Infectious Diseases, 2012, 12, 217.	1.3	42
143	Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure. Clinical Research in Cardiology, 2011, 100, 335-342.	1.5	42
144	Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema. International Journal of Cardiology, 2009, 135, 165-174.	0.8	22

#	Article	IF	Citations
145	Levels of oxidized low-density lipoproteins are increased in patients with severe sepsis. Journal of Critical Care, 2008, 23, 537-541.	1.0	15
146	Long-term prognostic value of midregional pro-adrenomedullin and C-terminal pro-endothelin-1 in patients with acute myocardial infarction. Clinical Chemistry and Laboratory Medicine, 2008, 46, 204-11.	1.4	21
147	Time-course of neopterin levels in patients suffering from severe sepsis treated with and without Drotrecogin-alpha (activated). Scandinavian Journal of Infectious Diseases, 2008, 40, 503-508.	1.5	3